FY2030 Earnings Forecast for ACHV Issued By HC Wainwright

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – HC Wainwright issued their FY2030 EPS estimates for Achieve Life Sciences in a report issued on Monday, January 26th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will post earnings of $1.64 per share for the year. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Other analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. Citizens Jmp started coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They issued a “market outperform” rating and a $19.00 price objective for the company. Raymond James Financial restated a “strong-buy” rating on shares of Achieve Life Sciences in a report on Monday, November 24th. Finally, Citigroup began coverage on shares of Achieve Life Sciences in a research note on Tuesday, November 25th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $4.61 on Tuesday. The company has a current ratio of 5.14, a quick ratio of 5.14 and a debt-to-equity ratio of 0.26. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $6.03. The stock has a market capitalization of $245.39 million, a P/E ratio of -3.34 and a beta of 1.71. The business’s fifty day moving average price is $4.85 and its 200 day moving average price is $3.88.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Achieve Life Sciences during the 1st quarter worth about $32,000. Next Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the third quarter valued at approximately $51,000. Sender Co & Partners Inc. purchased a new stake in shares of Achieve Life Sciences during the second quarter worth $56,000. OneDigital Investment Advisors LLC purchased a new position in Achieve Life Sciences during the third quarter worth approximately $63,000. Finally, Bank of America Corp DE boosted its position in shares of Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 9,617 shares during the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.